US20040019204A1 - Intramolecular amidation of sulfamate esters catalyzed by metalloporphyrins - Google Patents
Intramolecular amidation of sulfamate esters catalyzed by metalloporphyrins Download PDFInfo
- Publication number
- US20040019204A1 US20040019204A1 US10/202,581 US20258102A US2004019204A1 US 20040019204 A1 US20040019204 A1 US 20040019204A1 US 20258102 A US20258102 A US 20258102A US 2004019204 A1 US2004019204 A1 US 2004019204A1
- Authority
- US
- United States
- Prior art keywords
- metalloporphyrin
- catalyst
- sulfamate
- ruthenium
- amidation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OUMWIQYQZPMFHA-UHFFFAOYSA-N O=CC123N4C5=CC=C4/C(C4=C(F)C(F)=C(F)C(F)=C4F)=C4/C=CC(=N41)/C(C1=C(F)C(F)=C(F)C(F)=C1F)=C1/C=CC(=C(C4=C(F)C(F)=C(F)C(F)=C4F)C4=N2/C(=C\5C2=C(F)C(F)=C(F)C(F)=C2F)C=C4)N13 Chemical compound O=CC123N4C5=CC=C4/C(C4=C(F)C(F)=C(F)C(F)=C4F)=C4/C=CC(=N41)/C(C1=C(F)C(F)=C(F)C(F)=C1F)=C1/C=CC(=C(C4=C(F)C(F)=C(F)C(F)=C4F)C4=N2/C(=C\5C2=C(F)C(F)=C(F)C(F)=C2F)C=C4)N13 OUMWIQYQZPMFHA-UHFFFAOYSA-N 0.000 description 3
- SDFWQILPFBZQLP-HHAKTFQUSA-N O=CC123N4C5=CC=C4/C(C4=C6C(=CC7=C4[C@H]4CC[C@@H]7C4)[C@@H]4CC[C@H]6C4)=C4/C=CC(=N41)/C(C1=C4C(=CC6=C1[C@H]1CC[C@@H]6C1)[C@@H]1CC[C@H]4C1)=C1/C=CC(=C(C4=C6C(=CC7=C4[C@H]4CC[C@@H]7C4)[C@@H]4CC[C@H]6C4)C4=N2/C(=C\5C2=C5C(=CC6=C2[C@H]2CC[C@@H]6C2)[C@@H]2CC[C@H]5C2)C=C4)N13 Chemical compound O=CC123N4C5=CC=C4/C(C4=C6C(=CC7=C4[C@H]4CC[C@@H]7C4)[C@@H]4CC[C@H]6C4)=C4/C=CC(=N41)/C(C1=C4C(=CC6=C1[C@H]1CC[C@@H]6C1)[C@@H]1CC[C@H]4C1)=C1/C=CC(=C(C4=C6C(=CC7=C4[C@H]4CC[C@@H]7C4)[C@@H]4CC[C@H]6C4)C4=N2/C(=C\5C2=C5C(=CC6=C2[C@H]2CC[C@@H]6C2)[C@@H]2CC[C@H]5C2)C=C4)N13 SDFWQILPFBZQLP-HHAKTFQUSA-N 0.000 description 3
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
- B01J31/1805—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
- B01J31/181—Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
- B01J31/1825—Ligands comprising condensed ring systems, e.g. acridine, carbazole
- B01J31/183—Ligands comprising condensed ring systems, e.g. acridine, carbazole with more than one complexing nitrogen atom, e.g. phenanthroline
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0215—Sulfur-containing compounds
- B01J31/0222—Sulfur-containing compounds comprising sulfonyl groups
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0235—Nitrogen containing compounds
- B01J31/0245—Nitrogen containing compounds being derivatives of carboxylic or carbonic acids
- B01J31/0247—Imides, amides or imidates (R-C=NR(OR))
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0271—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds also containing elements or functional groups covered by B01J31/0201 - B01J31/0231
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
- B01J31/1805—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
- B01J31/181—Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
- B01J31/1825—Ligands comprising condensed ring systems, e.g. acridine, carbazole
- B01J31/183—Ligands comprising condensed ring systems, e.g. acridine, carbazole with more than one complexing nitrogen atom, e.g. phenanthroline
- B01J31/1835—Ligands comprising condensed ring systems, e.g. acridine, carbazole with more than one complexing nitrogen atom, e.g. phenanthroline comprising aliphatic or saturated rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/20—Carbonyls
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
- B01J2231/46—C-H or C-C activation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
- B01J2531/0238—Complexes comprising multidentate ligands, i.e. more than 2 ionic or coordinative bonds from the central metal to the ligand, the latter having at least two donor atoms, e.g. N, O, S, P
- B01J2531/0241—Rigid ligands, e.g. extended sp2-carbon frameworks or geminal di- or trisubstitution
- B01J2531/025—Ligands with a porphyrin ring system or analogues thereof, e.g. phthalocyanines, corroles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/10—Complexes comprising metals of Group I (IA or IB) as the central metal
- B01J2531/16—Copper
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/70—Complexes comprising metals of Group VII (VIIB) as the central metal
- B01J2531/72—Manganese
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/821—Ruthenium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/825—Osmium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/84—Metals of the iron group
- B01J2531/842—Iron
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/84—Metals of the iron group
- B01J2531/845—Cobalt
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2540/00—Compositional aspects of coordination complexes or ligands in catalyst systems
- B01J2540/20—Non-coordinating groups comprising halogens
- B01J2540/22—Non-coordinating groups comprising halogens comprising fluorine, e.g. trifluoroacetate
- B01J2540/225—Non-coordinating groups comprising halogens comprising fluorine, e.g. trifluoroacetate comprising perfluoroalkyl groups or moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the invention relates to methods for the direct intramolecular amidation of sulfamate esters affording cyclic sulfamidates. More particularly, the method represents an example of asymmetric intramolecular amidation of sulfamate ester with high ee values.
- Cyclic sulfamidate or sulfonamide is useful building block for drug discovery.
- Major recent pharmaceutical applications include the carbapenem antibiotic L-786,392 (Compound 3, see FIG. 2), and brinzolamide (Compound 4, see FIG. 2) for the treatment of glaucoma (Rosen et al., Science (1999), 283, 703; Dauban et al., Org. Lett. (2000), 2, 2327; Dauban et al., and Tetrahedron Lett. (2001), 42, 1037. FIG. 2).
- Cyclic sulfamidate has also been utilized in the preparation of amino acids (Baldwin et al., Tetrahedron: Asymmetry (1990), 1, 881; Boulton et al., J Chem. Soc., Perkin Trans. (1999), 1, 1421; and Halcomb et al., J Am. Chem. Soc. (2002), 124, 2534), and serves as chiral auxiliaries (Oppolzer et al., Tetrahedron Lett. (1994), 35, 3509; Ahn et al., Tetrahedron Lett. (1998), 39, 6321; and Lin et al., Tetrahedron (1999), 55, 13983).
- the present invention provides for the first time (1) intramolecular amidation of sulfamate esters catalyzed by a metalloporphyrin and (2) asymmetric intramolecular amidation of sulfamidate esters catalyzed by a transition-metal complex.
- the target cyclic sulfamidates can be easily converted to ⁇ or ⁇ amino alcohol (Du Bois et al., J Am. Chem. Soc. (2001), 123, 6935), which is an important precursor for drug synthesis and for the synthesis chiral ligands for asymmetric catalysis (Kajiro et al., Synlett (1998), 51; Davies et al., Tetrahedron Lett. (1996), 37, 813; Ghosh et al., J Am. Chem. Soc. (1996), 118, 2527).
- the present invention relates to a method for synthesizing a cyclic sulfamidate from a sulfamate ester comprising the step of catalyzing the reaction of an oxidant and a base with said sulfamate ester with a catalytic amount of metalloporphyrin as catalyst for producing the cyclic sulfamidate.
- the sulfamate ester is a compound comprising a sulfonylamide functional group.
- the oxidant is selected from the group consisting of PhI(OAc) 2 , PhIO, and NBS.
- the solvent for the reaction is acetonitrile, DMF, CH 2 Cl 2 or benzene.
- the base is Al 2 O 3 , MgO, ZnO, K 2 CO 3 , and KOH.
- the catalyst has the following structure:
- M is a metal, preferably a transition metal, most preferably ruthenium.
- the catalyst has the following structure:
- M is a metal, preferably a transition metal, most preferably ruthenium.
- FIG. 1 provides representative examples of the metalloporphyrin catalysts capable of catalyzing intramolecular amidation of sulfamate esters with high efficiency and high diastereo- or enantioselectivity.
- FIG. 2 provides representative examples of drugs containing cyclic sulfonamide unit.
- FIG. 3 illustrates the described method involving the direct intramolecular amidation of sulfamate esters using metalloporphyrin as a general and efficient catalyst.
- FIG. 4 provides representative examples of intramolecular amidation of sulfamate esters catalyzed by electron-deficient ruthenium porphyrin yielding the corresponding cyclic sulfamidates in good to excellent yields with excellent diastereoselectivity.
- FIG. 5 provides representative examples of intramolecular amidation of sulfamate esters catalyzed by electron-deficient ruthenium porphyrin with high turnover numbers.
- FIG. 6 provides representative examples of asymmetric intramolecular amidation of sulfamate esters catalyzed by chiral ruthenium porphyrin with high enantioselectivity.
- FIG. 7. provides representative examples of pharmaceutical application of ⁇ -amino alcohol.
- the present invention provides a non-chiral metalloporphyrin catalyst represented by the structure:
- M is a metal, preferably a transition metal such as ruthenium, manganese, iron, osmium, copper or cobalt, and most preferably ruthenium.
- the metalloporphyrin is a transition metal metalloporphyrin, such as ruthenium, manganese, iron, osmium, copper or cobalt metalloporphyrin.
- the porphyrin ligand is a tetraphenylporphyrin and the phenyl rings are attached at the meso positions of the porphyrin.
- catalysts are capable of exhibiting both regioselectivity and stereoselectivity.
- the catalyst is capable of selectively catalyzing intramolecular amidation of saturated C—H bonds. In another embodiment of the present invention, the catalyst is capable of catalyzing asymmetric intramolecular amidation of saturated C—H bonds. In one embodiment of this invention, the stereoselectivity is for the formation of only cis-configuration cyclic sulfamidates.
- the present invention provides a method for preparation of cyclic sulfamidates with the catalysts from sulfamate esters. Further, the present invention provides a method for producing a cis-cyclic sulfamidate with the catalyst. The present invention also provides a method for producing an optically active cyclic sulfamidate with the catalyst.
- the substrate is a sulfamate ester, a sulfamate ester derivative, or a hydrocarbon containing sulfonylamide group.
- solvents known in the art can be used to carry out the reaction.
- solvents include but are not limited to acetonitrile, DMF, CH 2 Cl 2 , and benzene.
- bases know in the art can be used. Such bases include but are not limted to Al 2 O 3 , MgO, ZnO, K 2 CO 3 , and KOH.
- the term “stereoselective” refers to selection of an optical isomer and the term “enantioselectivity” represents the maximal asymmetric induction and minimal racemization of the optically active products.
- the term “turnover” refers to the relative number of molecules of products per number of molecules of catalyst prior to the exhaustion of a given reaction.
- the invention relates to a direct method of synthesis of cyclic sulfamidates using ruthenium porphyrin (Compound/Catalyst 1, see FIG. 1, prepared according to: Murahashi et al., Tetrahedron Lett. 1995, 36,8059; Groves et al., J Am. Chem. Soc. 1996, 118, 8961) as a general and effective catalyst for the direct intramolecular amidation of sulfamate esters.
- ruthenium porphyrin Compound/Catalyst 1, see FIG. 1, prepared according to: Murahashi et al., Tetrahedron Lett. 1995, 36,8059; Groves et al., J Am. Chem. Soc. 1996, 118, 8961
- the commercially available Al 2 O 3 was dried to constant weight at 250° C. for 12 hours.
- Dichloromethane was freshly distilled from CaH 2 immediately prior to use.
- the reaction mixture was cooled to 25° C., diluted with 5 mL of CH 2 Cl 2 , and filtered through a pad of celite.
- Spectral data for Compound 16 are: 1 H NMR (CDCI 3 , 400 MHz) 7.37 (m, 5H), 4.60 (m, 1H), 4.39 (m, 2H), 2.14 (m, 1H), 1.10-1.85 (m, 8H) ppm; 13 C NMR (CDCl 3 , 100 MHz) 136.7, 129.3, 129.1, 127.3, 86.9, 64.3, 45.3, 31.8, 29.7, 24.8, 24.4 ppm; HRMS (EI) calcd. for C 13 H 17 NO 3 S:267.0929, found: 267.0935.
- the reaction temperature has effect on the ee values as well.
- benzene was used as solvent, lowering reaction temperature resulted in increase in ee values (entries B and C in FIG. 6: from 79 to 84%; entries E and F in FIG. 6: from 82 to 87%; entries H and I in FIG. 6: from 81 to 82%).
- the present invention provides a powerful method for the synthesis of chiral cyclic sulfamidates. These compounds are potentially useful for the synthesis of optically active ⁇ or ⁇ -amino alcohol, which is of particular importance for drug synthesis.
- optically-active Compound 17 (see FIG. 7) is currently receiving considerable attention as the key component of HIV protease inhibitor, indinavir Compound 18 (see: Hiyama et al., Synlett (1998), 51. FIG. 7).
- Compound 17 can be easily prepared from (1S2R)-Compound 14 (see FIG. 7) after hydrolysis (see: Du Bois et al., J Am. Chem. Soc. (2001), 123, 6935).
Abstract
The present invention relates to novel intramolecular amidation processes for substrates such as sulfamate esters using chiral and non-chiral metalloporphyrin complexes, which can maximize catalytic activity and enhance efficiency, stereoselectivity and speed of amidation of these substrates. The intramolecular amidation of sulfamate ester exhibits excellent cis-selectivity, affording cyclic sulfamidates with high ee values catalyzed by chiral metalloporphyrin.
Description
- The invention relates to methods for the direct intramolecular amidation of sulfamate esters affording cyclic sulfamidates. More particularly, the method represents an example of asymmetric intramolecular amidation of sulfamate ester with high ee values.
- Cyclic sulfamidate or sulfonamide is useful building block for drug discovery. Major recent pharmaceutical applications include the carbapenem antibiotic L-786,392 (Compound 3, see FIG. 2), and brinzolamide (Compound 4, see FIG. 2) for the treatment of glaucoma (Rosen et al.,Science (1999), 283, 703; Dauban et al., Org. Lett. (2000), 2, 2327; Dauban et al., and Tetrahedron Lett. (2001), 42, 1037. FIG. 2). Cyclic sulfamidate has also been utilized in the preparation of amino acids (Baldwin et al., Tetrahedron: Asymmetry (1990), 1, 881; Boulton et al., J Chem. Soc., Perkin Trans. (1999), 1, 1421; and Halcomb et al., J Am. Chem. Soc. (2002), 124, 2534), and serves as chiral auxiliaries (Oppolzer et al., Tetrahedron Lett. (1994), 35, 3509; Ahn et al., Tetrahedron Lett. (1998), 39, 6321; and Lin et al., Tetrahedron (1999), 55, 13983).
- Catalytic intramolecular amidation was pioneered by Breslow in 1983 using transition-metal porphyrin complexes and rhodium acetate as catalysts yielding cyclic sulfonamides (Breslow et al.,J Am. Chem. Soc. (1983), 105, 6728). Recent research by Du Bois showed that rhodium acetate served as an efficient catalyst for intramolecular amidation of sulfamate esters affording corresponding cyclic sulfamidates in good to high yield (Du Bois et al, J Am. Chem. Soc. (2001), 123, 6935). However, challenge remains to seek more stereoselective catalysts for the synthesis of optically active cyclic sulfamidates. There has been no report on asymmetric intramolecular amidation of such substrates using chiral catalysts.
- On the other hand, metalloporphyrin-catalyzed intermolecular nitrogen-atom transfer has attracted considerable attention not only because of its unique relationship to heme-containing enzymes but also because of its unusually high selectivity and catalytic turnover (Che et al.,Org. Lett. (2000), 2, 2233). Moderate ee values have been obtained for asymmetric aziridination of alkenes and amidation of saturated C—H bonds (Che et al., Chem. Comm. (1997), 2373; Che et al., Chem. Comm. (1999), 2377; Marchon et al., Chem. Comm. (1999), 989; and Che et al., Chem. Eur. J. (2002), 1563). The successful isolation of bis(tosylimido) ruthenium porphyrin provides useful insight into the mechanism of ruthenium porphyrin-catalyzed intramolecular nitrogen-atom transfer reactions (Che et al., J. Am. Chem. Soc. (1999), 121, 9120; and Che et al., Chem. Eur. J. (2002), 1563).
- The present invention provides for the first time (1) intramolecular amidation of sulfamate esters catalyzed by a metalloporphyrin and (2) asymmetric intramolecular amidation of sulfamidate esters catalyzed by a transition-metal complex. The target cyclic sulfamidates can be easily converted to α or β amino alcohol (Du Bois et al.,J Am. Chem. Soc. (2001), 123, 6935), which is an important precursor for drug synthesis and for the synthesis chiral ligands for asymmetric catalysis (Kajiro et al., Synlett (1998), 51; Davies et al., Tetrahedron Lett. (1996), 37, 813; Ghosh et al., J Am. Chem. Soc. (1996), 118, 2527).
- The present invention relates to a method for synthesizing a cyclic sulfamidate from a sulfamate ester comprising the step of catalyzing the reaction of an oxidant and a base with said sulfamate ester with a catalytic amount of metalloporphyrin as catalyst for producing the cyclic sulfamidate.
- In a preferred embodiment, the sulfamate ester is a compound comprising a sulfonylamide functional group.
- In a preferred embodiment, the oxidant is selected from the group consisting of PhI(OAc)2, PhIO, and NBS.
- In a preferred embodiment, the solvent for the reaction is acetonitrile, DMF, CH2Cl2 or benzene.
- In a preferred embodiment, the base is Al2O3, MgO, ZnO, K2CO3, and KOH.
-
- wherein M is a metal, preferably a transition metal, most preferably ruthenium.
-
- wherein M is a metal, preferably a transition metal, most preferably ruthenium.
- FIG. 1 provides representative examples of the metalloporphyrin catalysts capable of catalyzing intramolecular amidation of sulfamate esters with high efficiency and high diastereo- or enantioselectivity.
- FIG. 2 provides representative examples of drugs containing cyclic sulfonamide unit.
- FIG. 3 illustrates the described method involving the direct intramolecular amidation of sulfamate esters using metalloporphyrin as a general and efficient catalyst.
- FIG. 4 provides representative examples of intramolecular amidation of sulfamate esters catalyzed by electron-deficient ruthenium porphyrin yielding the corresponding cyclic sulfamidates in good to excellent yields with excellent diastereoselectivity.
- FIG. 5 provides representative examples of intramolecular amidation of sulfamate esters catalyzed by electron-deficient ruthenium porphyrin with high turnover numbers.
- FIG. 6 provides representative examples of asymmetric intramolecular amidation of sulfamate esters catalyzed by chiral ruthenium porphyrin with high enantioselectivity.
- FIG. 7. provides representative examples of pharmaceutical application of α-amino alcohol.
-
-
- wherein M is a metal, preferably a transition metal such as ruthenium, manganese, iron, osmium, copper or cobalt, and most preferably ruthenium.
- In one embodiment of this invention, the metalloporphyrin is a transition metal metalloporphyrin, such as ruthenium, manganese, iron, osmium, copper or cobalt metalloporphyrin.
- In one embodiment of this invention, the porphyrin ligand is a tetraphenylporphyrin and the phenyl rings are attached at the meso positions of the porphyrin.
- In one embodiment of the present invention, catalysts are capable of exhibiting both regioselectivity and stereoselectivity.
- In one embodiment of the present invention, the catalyst is capable of selectively catalyzing intramolecular amidation of saturated C—H bonds. In another embodiment of the present invention, the catalyst is capable of catalyzing asymmetric intramolecular amidation of saturated C—H bonds. In one embodiment of this invention, the stereoselectivity is for the formation of only cis-configuration cyclic sulfamidates.
- Additionally, the present invention provides a method for preparation of cyclic sulfamidates with the catalysts from sulfamate esters. Further, the present invention provides a method for producing a cis-cyclic sulfamidate with the catalyst. The present invention also provides a method for producing an optically active cyclic sulfamidate with the catalyst.
- In an embodiment of this invention, the substrate is a sulfamate ester, a sulfamate ester derivative, or a hydrocarbon containing sulfonylamide group.
- A number of solvents known in the art can used to carry out the reaction. Such solvents include but are not limited to acetonitrile, DMF, CH2Cl2, and benzene.
- A number of bases know in the art can be used. Such bases include but are not limted to Al2O3, MgO, ZnO, K2CO3, and KOH.
- As used herein, the term “stereoselective” refers to selection of an optical isomer and the term “enantioselectivity” represents the maximal asymmetric induction and minimal racemization of the optically active products. The term “turnover” refers to the relative number of molecules of products per number of molecules of catalyst prior to the exhaustion of a given reaction.
- Various publications are cited herein, the disclosures of which are incorporated by reference in their entirety for all purposes.
- Having described the invention, the following examples are included to illustrate the benefits of the present invention. The examples are only illustrative and are not meant to unduly limit the scope of the present invention.
- Intramolecular Amidation of Sulfamate Esters Catalyzed by Electron-Deficient Ruthenium Porphyrin (Compound/Catalyst 1)
- The invention relates to a direct method of synthesis of cyclic sulfamidates using ruthenium porphyrin (Compound/Catalyst 1, see FIG. 1, prepared according to: Murahashi et al.,Tetrahedron Lett. 1995, 36,8059; Groves et al., J Am. Chem. Soc. 1996, 118, 8961) as a general and effective catalyst for the direct intramolecular amidation of sulfamate esters.
- Typical conditions employ 1.5% of
Catalyst - With only 1.5% catalyst loading, sulfamate esters (Compounds/Substrates5-10, see FIG. 4) were converted into corresponding cyclic sulfamidates (Compounds/Products 11-16, see FIG. 4) with good to high yields (see FIG. 4). The highest yield (88%) was achieved on the intramolecular amidation of
Substrates Catalyst 1 not only shows high catalytic efficiency, but also shows excellent cis-selectivity. ForSubstrates cyclic sulfamidates ruthenium porphyrin 1 has better stereoselectivity than rhodium acetate (cis and trans mixture were obtained whenSubstrate 8 was catalyzed by rhodium acetate. The ratio of cis/trans is 8:1. See: Du Bois et al., J. Am. Chem. Soc. 2001, 123, 6935). The oxidant used in the catalytic reaction is PhI(OAc)2, which is commercially available. For Substrates 5-7, and 10, six- rather than five-membered heterocycles 10-12 and 16 were formed in high yields. Forsubstrates membered ring products - All the target cyclic sulfamidates were characterized by1H, 13C and NOESY NMR and HRMS. The spectral data of Products 11-14 are identical with those reported in the literature (see: Du Bois et al., J. Am. Chem. Soc. 2001, 123, 6935). Spectral data for
Compound 9 are: 1H NMR (CDCl3, 400 MHz):δ=7.29 (m, 5H), 4.82 (s, 2H), 4.37 (t, J=9.3 Hz, 2H), 3.03 (t, J=9.2 Hz, 2H); 13C NMR (CDCl3, 100 MHz):δ=136.4, 128.9, 128.7, 127.0, 71.4, 35.2. HRMS (EI) calcd. for C8H11NO3S: 201.0460, found: 201.0456. Spectral data forCompound 10 are: 1H NMR (CDC13, 400 MHz) 7.23 (m, 5H), 4.66 (s, 2H), 4.34 (m, 1H), 3.15 (dd, 1H, J=13.6 Hz), 2.32 (m, 2H), 1.10-1.86 (m, 8H) ppm; 13C NMR (CDCl3, 100 MHz) 140.0, 129.2, 128.3, 126.0, 87.2, 44.0, 38.9, 32.4, 30.0, 24.5, 24.4 ppm; HRMS (EI) calcd. for C13H19NO3S:269.1087, found: 269.1090. Spectral data forCompound 15 are: 1H NMR (CDCl3, 400 MHz) 7.43 (m, 5H), 5.07 (m, 1H), 4.84 (m, 2H), 4.45 (t, J=6.5 Hz, 1H) ppm; 13C NMR (CDCl3, 100 MHz) 135.3, 129.5, 129.4, 126.7, 75.0, 59.6 ppm; HRMS (EI) calcd. for C8H9NSO3:199.0303, found: 199.0297. Spectral data forCompound 16 are: 1H NMR (CDCI3, 400 MHz) 7.37 (m, 5H), 4.60 (m, 1H), 4.39 (m, 2H), 2.14 (m, 1H), 1.10-1.85 (m, 8H) ppm; 13C NMR (CDCl3, 100 MHz) 136.7, 129.3, 129.1, 127.3, 86.9, 64.3, 45.3, 31.8, 29.7, 24.8, 24.4 ppm; HRMS (EI) calcd. for C13H17NO3S:267.0929, found: 267.0935. - Turnover refers to the relative number of molecules of products per number of molecules of catalyst prior to the exhaustion of a given reaction and shows a very important aspect of catalyst efficiency. The turnover numbers of rhodium catalyst don't excess 50 (see: Du Bois et al.,J Am. Chem. Soc. (2001), 123, 6935). With electron-
deficient ruthenium porphyrin 1 as catalyst, intramolecular amidation of 5 and 7 afforded 290 and 301 turnover numbers, respectively (FIG. 5). This shows thatcatalyst 1 is more robust than rhodium catalysts (the reaction condition are almost the same as those example 1, except that lower catalyst loading was employed in example 2. See the footnote of FIG. 5). - Asymmetric Intramolecular Amidation of Sulfamate Ester Catalyzed by Chiral Ruthenium Porphyrin (Compound/Catalyst2)
- With chiral ruthenium porphyrin (Compound/
Catalyst 2 in FIG. 1) (prepared according to: Che et al., Chem. Comm. (1997), 1205) as catalyst, sulfamate esters (Compounds/Substrates sulfamate ester 5 was converted into 11 with 46% ee when the reaction was performed in CH2Cl2 (entry A of FIG. 6). But the ee value increased sharply to 79% when benzene was used as solvent (entry B of FIG. 6). Same conclusion can be obtained forSubstrates - The reaction temperature has effect on the ee values as well. When benzene was used as solvent, lowering reaction temperature resulted in increase in ee values (entries B and C in FIG. 6: from 79 to 84%; entries E and F in FIG. 6: from 82 to 87%; entries H and I in FIG. 6: from 81 to 82%).
- The present invention provides a powerful method for the synthesis of chiral cyclic sulfamidates. These compounds are potentially useful for the synthesis of optically active α or β-amino alcohol, which is of particular importance for drug synthesis. For example, optically-active Compound17 (see FIG. 7) is currently receiving considerable attention as the key component of HIV protease inhibitor, indinavir Compound 18 (see: Hiyama et al., Synlett (1998), 51. FIG. 7).
Compound 17 can be easily prepared from (1S2R)-Compound 14 (see FIG. 7) after hydrolysis (see: Du Bois et al., J Am. Chem. Soc. (2001), 123, 6935). From commercially available and non-chiral 2-indanol,Compound 17 can be obtained through 3 steps. However, it took eight steps to yieldCompound 17 from chiral amino acid as starting material (see: Hiyama et al., Synlett (1998), 51).
Claims (15)
1. A method for synthesizing a cyclic sulfamidate from a sulfamate ester comprising the step of catalyzing the reaction of an oxidant and a base with said sulfamate ester with a catalytic amount of metalloporphyrin as catalyst for producing the cyclic sulfamidate.
2. The method according to claim 1 wherein the sulfamate ester is a compound comprising a sulfonylamide functional group.
3. The method according to claim 1 wherein the oxidant is selected from the group consisting of PhI(OAc)2, PhIO, and NBS.
4. The method according to claim 1 further comprising an organic solvent selected from the group consisting of acetonitrile, DMF, CH2Cl2, and benzene.
5. The method according to claim 1 wherein the base is selected from the group consisting of Al2O3, MgO, ZnO, K2CO3, and KOH.
6. The method accoring to claim 1 wherein the metalloporphyrin is a transition metal metalloporphyrin.
7. The method according to claim 6 wherein the transition metal metalloporphyrin is selected from the group consisting of ruthenium, manganese, iron, cobalt, copper and osmium metalloporphyrin.
8. The method according to claim 7 , wherein the metalloporphyrin is ruthenium porphyrin.
10. The method of claim 9 wherein M is ruthenium.
11. The method of claim 9 wherein the catalyst exhibits cis-selectivity.
13. The method of claim 12 wherein M is ruthenium.
14. The method of claim 12 wherein the catalyst exhibit cis-selectivity.
15. The method of claim 12 wherein the catalyst exhibits enantioselctivity and yields corresponding cyclic sulfamidate with high ee value.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/202,581 US20040019204A1 (en) | 2002-07-23 | 2002-07-23 | Intramolecular amidation of sulfamate esters catalyzed by metalloporphyrins |
EP03102223A EP1384718A1 (en) | 2002-07-23 | 2003-07-18 | Intramolecular amidation of sulfamate esters catalyzed by metalloporphyrins |
US10/790,810 US7105660B2 (en) | 2002-07-23 | 2004-03-03 | Intramolecular amidation of sulfamates catalyzed by metalloporphyrins |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/202,581 US20040019204A1 (en) | 2002-07-23 | 2002-07-23 | Intramolecular amidation of sulfamate esters catalyzed by metalloporphyrins |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/790,810 Continuation-In-Part US7105660B2 (en) | 2002-07-23 | 2004-03-03 | Intramolecular amidation of sulfamates catalyzed by metalloporphyrins |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040019204A1 true US20040019204A1 (en) | 2004-01-29 |
Family
ID=30000100
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/202,581 Abandoned US20040019204A1 (en) | 2002-07-23 | 2002-07-23 | Intramolecular amidation of sulfamate esters catalyzed by metalloporphyrins |
US10/790,810 Expired - Lifetime US7105660B2 (en) | 2002-07-23 | 2004-03-03 | Intramolecular amidation of sulfamates catalyzed by metalloporphyrins |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/790,810 Expired - Lifetime US7105660B2 (en) | 2002-07-23 | 2004-03-03 | Intramolecular amidation of sulfamates catalyzed by metalloporphyrins |
Country Status (2)
Country | Link |
---|---|
US (2) | US20040019204A1 (en) |
EP (1) | EP1384718A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070281915A1 (en) * | 2002-12-23 | 2007-12-06 | Destiny Pharma Limited | Porphyrin Derivatives and Their Use in Photodynamic Therapy |
US7977474B2 (en) | 2004-06-23 | 2011-07-12 | Destiny Pharma Ltd. | Uses of porphyrin compounds |
CN115779893A (en) * | 2022-12-19 | 2023-03-14 | 江南大学 | H 2 TPPS-arginine assembly mediated chiral noble metal nano catalyst and preparation method thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110207956A1 (en) * | 2010-02-24 | 2011-08-25 | Zhang X Peter | Intramolecular c-h amination with phosphoryl azides |
KR101286617B1 (en) * | 2010-06-21 | 2013-07-23 | 한국화학연구원 | Method for preparing [1,2,3]-oxathiazolidine-2,2-dioxide or [1,2,5]-thiadiazolidine-1,1-dioxide derivatives |
KR101955702B1 (en) * | 2011-07-31 | 2019-03-07 | 사우디 아라비안 오일 컴퍼니 | Integrated process to produce asphalt and desulfurized oil |
CN104961741A (en) * | 2015-06-10 | 2015-10-07 | 华中师范大学 | High-steric hindrance chiral porphyrin, preparation method thereof, and application thereof in metalloporphyrin |
-
2002
- 2002-07-23 US US10/202,581 patent/US20040019204A1/en not_active Abandoned
-
2003
- 2003-07-18 EP EP03102223A patent/EP1384718A1/en not_active Withdrawn
-
2004
- 2004-03-03 US US10/790,810 patent/US7105660B2/en not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070281915A1 (en) * | 2002-12-23 | 2007-12-06 | Destiny Pharma Limited | Porphyrin Derivatives and Their Use in Photodynamic Therapy |
US8084602B2 (en) | 2002-12-23 | 2011-12-27 | Destiny Pharma Limited | Porphyrin derivatives and their use in photodynamic therapy |
US7977474B2 (en) | 2004-06-23 | 2011-07-12 | Destiny Pharma Ltd. | Uses of porphyrin compounds |
CN115779893A (en) * | 2022-12-19 | 2023-03-14 | 江南大学 | H 2 TPPS-arginine assembly mediated chiral noble metal nano catalyst and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US20040236099A1 (en) | 2004-11-25 |
EP1384718A1 (en) | 2004-01-28 |
US7105660B2 (en) | 2006-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fruit et al. | Asymmetric transfer of nitrenes catalyzed by chiral dirhodium (II) using aromatic sulfamate esters | |
Jin et al. | Chiral rare earth metal complex-catalyzed conjugate addition of O-alkylhydroxylamines. An efficient synthetic entry into optically active 2-acyl aziridines | |
Anas et al. | Routes toward enantiopure 2-substituted indolines: an overview | |
Barlan et al. | Development and application of versatile bis-hydroxamic acids for catalytic asymmetric oxidation | |
Liu et al. | DpenPhos/Rh (I) Catalyzed Asymmetric Hydrogenation of Dehydro-β-Amino Acid Esters | |
US9334297B2 (en) | Chiral imidazolium salts for asymmetric catalysis | |
Yanagisawa et al. | Asymmetric protonations of enol derivatives | |
Yu et al. | Enantioselective Ag (I)-catalyzed [3+ 2] cycloaddition of azomethine ylides using a chiral ferrocene-based phosphine–phosphoramidite ligand having a stereogenic P-center | |
CN112824422B (en) | Chiral ferrocene-indole diphosphine ligand as well as preparation method and application thereof | |
Chen et al. | Bifunctional AgOAc-catalyzed asymmetric reactions | |
US20040019204A1 (en) | Intramolecular amidation of sulfamate esters catalyzed by metalloporphyrins | |
Kubota et al. | Strained silacycle-catalyzed asymmetric Diels–Alder cycloadditions: the first highly enantioselective silicon Lewis acid catalyst | |
KR20020009485A (en) | Process for producing optically active alcohol | |
CN114437103A (en) | Method for synthesizing chiral tetrahydrobenzoxepin compound through gold-catalyzed asymmetric cycloaddition reaction | |
US7385064B1 (en) | Catalysts for use in enantioselective synthesis | |
CN112940002B (en) | Method for synthesizing octatomic bridged ring compound through palladium-catalyzed asymmetric ring addition reaction | |
Han et al. | Chiral ferrocenyl P, S-ligands for highly efficient copper-catalyzed asymmetric [3+ 2] cycloaddition of azomethine ylides | |
JP7464234B2 (en) | Method for producing highly optically active allene carboxylic acid compounds having axial asymmetry | |
Liu et al. | Enantiodivergent synthesis of 1, 2-bis (diphenylphosphino) ethanes via asymmetric [3+ 2]-cycloaddition | |
JP2012512136A (en) | Aluminum complexes and their use as catalysts in intramolecular ring closure reactions | |
CN110724112A (en) | Bisoxazoline ligand compound and synthetic method thereof | |
Zou et al. | New bis (1-ferrocenylethyl) amine-derived monodentate phosphoramidite ligands for highly enantioselective copper-catalyzed 1, 4-conjugate addition | |
CN114516814B (en) | Catalytic asymmetric preparation method of chiral quaternary carbon alpha-amino acid ester compound | |
CN113173862B (en) | Method for synthesizing olefin by selective desaturation of inert carbon-carbon bond | |
CN111848320B (en) | Synthesis method of chiral 2-hydroxy-1, 4-dicarbonyl compound and pantolactone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF HONG KONG, THE, CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHE, CHI-MING;LIANG, JIANG-LIN;REEL/FRAME:013421/0474 Effective date: 20020805 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |